Meeting
2021 ASCO Annual Meeting
A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.
Authors
Hatem Hussein Soliman
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Hatem Hussein Soliman , Hyo S. Han , Deanna Hogue , Blaise Mooney , Ricardo L Costa , Marie Catherine Lee , Bethany Niell , Angela Williams , Alec Chau , Shannon Falcon , Nazanin Khakpour , Aixa Soyano , Avan J. Armaghani , Robert J Weinfurtner , Susan Hoover , John Kiluk , Marilin Rosa , Brooke Fridley , Hung T. Khong , Brian J. Czerniecki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02779855
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 578)
DOI
10.1200/JCO.2021.39.15_suppl.578
Abstract #
578
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2014 ASCO Annual Meeting
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9.
First Author: Jame Abraham
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji